--- title: RPMI-8226 CDX Model - TD2 Precision Oncology description: RPMI-8226 stands as a key cell line for multiple myeloma research, elucidating the disease's molecular intricacies and spearheading therapeutic innovations. image: https://td2inc.com/hubfs/Assets/GraphsFigures/rpmi-8226.jpg --- ×   [![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en) ![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png) [![td2-logo](https://td2inc.com/hubfs/td2-logo.png "td2-logo")](https://td2inc.com/?hsLang=en) ![Search Site](https://td2inc.com/hubfs/Assets/Icon/search-icon-1.png) # RPMI-8226 CDX Model The RPMI-8226 cell line is derived from human multiple myeloma, a cancer of plasma cells that primarily affects the bone marrow. Multiple myeloma is marked by its production of abnormal antibodies and its potential to cause bone lesions, anemia, and kidney dysfunction. The RPMI-8226 cell line serves as a robust platform for studying the complex biology, progression, and therapeutic challenges associated with multiple myeloma. Featuring distinct molecular features and genetic markers typically found in myeloma patients, RPMI-8226 is of paramount importance in preclinical studies. Its in vitro and in vivo behavior provides crucial insights into tumor growth dynamics, interaction with the bone marrow microenvironment, and response to therapeutic agents. Researchers leverage the RPMI-8226 model extensively to delve into the molecular and cellular dynamics of multiple myeloma, assess the efficacy of novel therapeutic compounds, and investigate potential resistance pathways to standard treatments. ## Model Details **Cancer Location:** Bone Marrow **Cancer Type:** Multiple Myeloma **Model Name:** RPMI-8226 **Mouse Strain:** NOD SCID, NSG **Treatment Data Available:** Chemotherapy (Bortezomib, Velcade) ## RPMI-8226 Growth Curves ![RPMI-8226 CDX Model](https://td2inc.com/hubfs/Assets/GraphsFigures/rpmi-8226.jpg) Growth of subcutaneous RPMI-8226 in NOD SCID mice (n=10 mice) ### Request Additional CDX Model Data ## CONTACT US ## Get Started. Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started. [Get Started Now](https://td2inc.com/contact-us/?hsLang=en) [![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/td2-logo.png?width=160&name=td2-logo.png)](https://td2inc.com/?hsLang=en) Office 13208 E. Shea Blvd, Suite 100 Scottsdale, AZ 85259 Phone (602) 358-8300 Connect with us - - ![td2-logo-footer](https://td2inc.com/hs-fs/hubfs/Assets/Logo/acclac-logo.png?width=139&name=acclac-logo.png) © 2026 Translational Drug Development. All Rights Reserved. [Terms and Conditions](https://td2inc.com/terms-and-conditions?hsLang=en) | [Privacy Policy](https://td2inc.com/privacy-policy?hsLang=en)